Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides

Atherosclerosis

Volumn 236, Issue 2, 2014, Pages 244-250

  Prenner, Stuart B ^a   Mulvey, Claire K ^a   Ferguson, Jane F ^a   Rickels, Michael R ^a   Bhatt, Anish B ^a   Reilly, Muredach P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Subclinical atherosclerosis; Triglycerides; VLDL C

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; HEMOGLOBIN A1C; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIDIABETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE DURATION; EXERCISE; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BLOOD PRESSURE; CALCINOSIS; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DRINKING BEHAVIOR; ETHNIC GROUP; HYPERLIPIDEMIAS; MIDDLE AGED; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SMOKING; UNITED STATES;

AGED; ALCOHOL DRINKING; APOLIPOPROTEINS B; BLOOD PRESSURE; BODY MASS INDEX; CALCINOSIS; CHOLESTEROL, VLDL; COMORBIDITY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; ETHNIC GROUPS; EXERCISE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PENNSYLVANIA; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING; TRIGLYCERIDES;

EID: 84907084567     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.07.008     Document Type: Article

References (50)

1. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
2. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
3. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the copenhagen male study. Circulation 1998, 97:1029-1036.
4. Patel A., Barzi F., Jamrozik K., et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation 2004, 110:2678-2686.
5. Di Angelantonio E., Sarwar N., et al. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc 2009, 302:1993-2000. Emerging Risk Factors, C.
6. Sarwar N., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. Triglyceride Coronary Disease Genetics, C, emerging risk factors, C.
7. Willer C.J., Schmidt E.M., et al. Discovery and refinement of loci associated with lipid levels. Nature Genetics 2013, 45:1274-1283. Global Lipids Genetics, C.
8. Do R., Willer C.J., Schmidt E.M., et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013, 45:1345-1352.
9. Bansal S., Buring J.E., Rifai N., Mora S., Sacks F.M., Ridker P.M. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. J Am Med Assoc 2007, 298:309-316.
10. Varbo A., Benn M., Tybjærg-Hansen A., Jørgensen A.B., Frikke-Schmidt R., Nordestgaard B.G. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013, 61:427-436.
11. Jialal I., Devaraj S. Remnant lipoproteins: measurement and clinical significance. Clin Chem 2002, 48:217-219.
12. Martin S.S., Qasim A.N., Mehta N.N., et al. Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites. Diabetes 2009, 58:1887-1892.
13. Hirany S., Li D., Jialal I. A more valid measurement of low-density lipoprotein cholesterol in diabetic patients. Am J Med 1997, 102:48-53.
14. Rifai N., Warnick G.R., McNamara J.R., Belcher J.D., Grinstead G.F., Frantz I.D. Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clin Chem 1992, 38:150-160.
15. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
16. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005, 112:2735-2752.
17. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte M., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990, 15:827-832.
18. Cassidy A.E., Bielak L.F., Kullo I.J., et al. Sex-specific associations of lipoprotein(a) with presence and quantity of coronary artery calcification in an asymptomatic population, medical science monitor. Int Med J Exp Clin Res 2004, 10:CR493-503.
19. Schwarz G.E. Estimating the dimension of a model. Ann Stat 1978, 6:461-464.
20. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control 1974, 19:716-723.
21. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109-2122.
22. Harchaoui K.E., Visser M.E., Kastelein J.J., Stroes E.S., Dallinga-Thie G.M. Triglycerides and cardiovascular risk. Curr Cardiology Reviews 2009, 5:216-222.
23. Garg A., Grundy S.M. Management of dyslipidemia in NIDDM. Diabetes Care 1990, 13:153-169.
24. Assmann G., Schulte H., Funke H., von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998, 19(Suppl. M):M8-M14.
25. Miller M., Cannon C.P., Murphy S.A., Qin J., Ray K.K., Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008, 51:724-730. PROVE IT-TIMI 22 Investigators.
26. Gianturco S.H., Bradley W.A. Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Clin Cardiol 1999, 22:II7-14.
27. Eisenberg S., Gavish D., Oschry Y., Fainaru M., Deckelbaum R.J. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest 1984, 74:470-482.
28. Rapp J.H., Lespine A., Hamilton R.L., et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque, arteriosclerosis and thrombosis. A Journal Vascular Biology / Am Heart Assoc 1994, 14:1767-1774.
29. Proctor S.D., Mamo J.C. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall-evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest 1998, 28:497-503.
30. Phillips N.R., Waters D., Havel R.J. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993, 88:2762-2770.
31. Brown M.S., Goldstein J.L. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 1983, 52:223-261.
32. Gianturco S.H., Brown F.B., Gotto A.M., Bradley W.A. Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts. J Lipid Res 1982, 23:984-993.
33. Warnick G.R., Albers J.J. Physiological and analytical variation in cholesterol and triglycerides. Lipids 1976, 11:203-208.
34. Fujioka Y., Ishikawa Y. Remnant lipoproteins as strong key particles to atherogenesis. J Atheroscler Thromb 2009, 16:145-154.
35. Zilversmit D.B. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995, 41:153-158.
36. Lu W., Resnick H.E., Jablonski K.A., et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003, 26:16-23.
37. Avogaro A., Giorda C., Maggini M., et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment, and geographic location. Diabetes Care 2007, 30:1241-1247.
38. Laakso M., Lehto S., Penttila¨ I., Pyo¨ra¨la¨ K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993, 88:1421-1430.
39. Walden C.E., Knopp R.H., Wahl P.W., Beach K.W., Strandness E. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. N Engl J Med 1984, 311:953-959.
40. Saha K.R., Rahman M.M., Paul A.R., et al. Changes in lipid profile of postmenopausal women. Mymensingh Med J 2013, 22:706-711.
41. van Beek A.P., de Ruijter-Heijstek F.C., Erkelens D.W., de Bruin T.W. Menopause is associated with reduced protection from postprandial lipemia, arteriosclerosis. Thrombosis, Vascular Biology 1999, 19:2737-2741.
42. Stensvold I., Tverdal A., Urdal P., Graff-Iversen S. Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 1993, 307:1318-1322.
43. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA J Am Med Assoc 2012, 307:1302-1309.
44. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006, 259:247-258.
45. Masuoka H., Kamei S., Wagayama H., et al. Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels. Am Heart J 2000, 139:305-310.
46. Musunuru K., Pirruccello J.P., Do R., et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010, 363:2220-2227.
47. Raggi P., Shaw L.J., Berman D.S., Callister T.Q. Prognostic value of coronary artery calcium screening in subjects with and without diabetes. J Am Coll Cardiol 2004, 43:1663-1669.
48. Detrano R., Guerci A.D., Carr J.J., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008, 358:1336-1345.
49. Kondos G.T., Hoff J.A., Sevrukov A., et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation 2003, 107:2571-2576.
50. Elkeles R.S., Godsland I.F., Feher M.D., et al. Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the predict study. Eur Heart J 2008, 29:2244-2251.